Celebrex In Acute Gouty Arthritis Study

• Drug: Indomethacin
  
  indomethacin 50 mg three times a day (TID) for 8 days.
• Drug: Celecoxib
  
  An initial dose of celecoxib 800 mg followed by a second dose of 400 mg 12 hours later on Day 1 (celecoxib 800/400 mg regimen) and continuing 400 mg two times a day (BID) for 7 days.
• Drug: Celecoxib
  
  An initial dose of celecoxib 400 mg followed by a second dose of 200 mg 12 hours later (celecoxib 400/200 mg regimen) and continuing 200 mg two times a day (BID) for 7 days.
• Drug: Celecoxib
  
  Celecoxib 50 mg two times a day (BID) for 8 days

• Active Comparator: 1
  
  Intervention: Drug: Indomethacin
• Experimental: 2
  
  Intervention: Drug: Celecoxib
• Experimental: 3
  
  Intervention: Drug: Celecoxib
• Experimental: 4
  
  Intervention: Drug: Celecoxib

Inclusion Criteria:

• Acute gouty arthritis meeting the American College of Rheumatology (ACR) criteria for acute arthritis of primary gout;
• Onset of pain from an acute gouty arthritis attack within 48 hours prior to Screening/Baseline (Visit 1);
• A rating of moderate, severe, or extreme (2, 3, or 4, respectively) on the Patient's assessment of pain intensity in the index joint (5-point scale:0-4) at Screening/Baseline.

Exclusion Criteria:

• Diagnosis of any other type of arthritis including those types suspected of being infectious in origin in the index joint or presence of any acute trauma of the index joint. Patients with osteoarthritis will be included as long as it is mild or moderate (according to investigator's criteria) and it does not affect the index joint;
• Acute polyarticular gout involving greater than 4 joints or chronic gout.